Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, strengthened its executive team with the appointment of two proven sales and marketing figures. The two management additions include Amy Griffith, the new vice president of strategy and business development, who will lead the development of strategic and tactical initiatives (https://ibn.fm/Stz6j), and Stuart Bernstein, the new vice president of marketing, who will be responsible for BRSF’s marketing strategy (https://ibn.fm/yfZYU).
The strategic move is designed to drive Brain Scientific’s revenue growth and expand its commercialization programs by leveraging the newly hired key executives’ wealth of experience and knowledge. As a commercial-stage, healthcare company disrupting the brain diagnostics market, Brain Scientific is committed to the rapid deployment of its unique technology, bringing its NeuroCap, a revolutionary hospital-grade disposable EEG headset, to as many patients as possible as quickly as possible.
Recent research indicates that more than one-third of coronavirus patients experience neurologic symptoms, a fact that adds greater urgency to the company’s efforts to bring the device to market. The NeuroCap offers fast testing with limited contact between medical staff and infected patients, a vital feature in the pandemic environment.
A leader in the development and commercialization of innovative life-changing technologies for patients, Brain Scientific is poised to seize the market opportunity opened up by the demand for remote EEG testing. To support its ambitious plans for the future, BRSF enhanced its executive team with seasoned industry figures with a proven track record of success.
As an established sales expert with years of experience in the medical and healthcare industries, including health giants such as GlaxoSmithKline, Griffith is a key addition to the management team. Griffith brings extraordinary credentials to Brain Scientific as the company continues to grow as the leader in routine EEG testing. Her experience in global marketing positioning will be critical to BRSF’s future success. With extensive expertise in developing new business opportunities and implementing effective sales strategies and impressive background in the neurology market, she will focus on ensuring the company is well prepared to execute on its next phase of growth.
Bernstein has more than 30 years of industry experience in marketing, sales and start-up leadership at companies in the medical devices and healthcare space. He has acquired a wealth of knowledge and skills ideal for leading Brain Scientific’s marketing strategy and propelling the company’s growth to new heights. Previously a CEO of BioSignal, an EEG medical device company, Bernstein is a proven industry veteran with in-depth knowledge and expertise necessary to implement a successful go to market strategy.
Bernstein will work collaboratively with Griffith to implement business strategies that support future growth. Together they are poised to set Brain Scientific on the path of growth, shaping the future of the brain diagnostics space.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective…
A team of researchers has leveraged a technique called temporal learning to train an AI…
Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year…
“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected…
Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive…
A new study focusing on twins has found that individuals with a larger presence of…